U.S. Online Retail and Ecommerce Stock News

NYSE:ED
NYSE:EDIntegrated Utilities

Consolidated Edison (ED) Faces A Valuation Test Following Mizuho Downgrade

Mizuho’s decision to downgrade Consolidated Edison (ED) to Neutral, citing constrained growth prospects and a less compelling valuation discount versus peers, has drawn fresh attention to the stock’s current pricing and risk profile. See our latest analysis for Consolidated Edison. Despite the recent Mizuho downgrade and earlier cautious commentary from Morgan Stanley, Consolidated Edison’s share price is at $110.76, with a year-to-date share price return of 10.77% and a 1-year total...
NasdaqGS:ALRM
NasdaqGS:ALRMSoftware

How Investors Are Reacting To Alarm.com (ALRM) Launching an AI Indoor Camera With Privacy Shutter

Earlier this month, Alarm.com announced the ADC-V530, a premium 4MP HDR indoor Wi‑Fi camera with color night vision, an integrated spotlight, updated AI video analytics, and a first‑of‑its‑kind physical privacy shutter that can be controlled and automated through the Alarm.com app. This launch extends Alarm.com’s video portfolio for both homes and small businesses while emphasizing hardware‑level privacy controls and AI‑driven monitoring capabilities across its platform. We’ll now examine...
NasdaqGS:STRL
NasdaqGS:STRLConstruction

Did Sterling’s Surging E‑Infrastructure Backlog and Raised Guidance Just Shift Sterling Infrastructure's (STRL) Investment Narrative?

Sterling Infrastructure recently reported strong quarterly results, a growing E-Infrastructure backlog tied to hyperscale data centers and semiconductor facilities, and reinforced its outlook with raised guidance. At the same time, sector-wide strength in engineering and construction and ongoing integration of new capabilities appear to be amplifying investor confidence in the company’s reshaped business mix. We’ll now examine how Sterling’s expanding E-Infrastructure project backlog may...
NYSE:BKU
NYSE:BKUBanks

BankUnited (BKU) Following Regional Growth Hopes Looks Close To Fair Value

With no single headline event driving attention, BankUnited (BKU) is drawing interest as investors reassess regional bank stocks, supported by its recent share performance and steady profitability metrics across revenue and net income. See our latest analysis for BankUnited. BankUnited's share price has gained 12.3% year to date and 12.9% over the past 90 days, while the 1 year total shareholder return of 45.8% and 3 year total shareholder return above 7x indicate strong momentum over both...
NYSE:MAS
NYSE:MASBuilding

Masco (MAS) Is Up 7.2% After Q1 Earnings Beat And Sector Strength - Has The Bull Case Changed?

Earlier this year, Masco reported a strong first quarter, with revenues surpassing analyst expectations and solid organic revenue and EBITDA growth across its home improvement portfolio. This performance came as the broader home construction materials sector also delivered better-than-expected results and guidance, reinforcing Masco’s exposure to a healthier-than-anticipated repair and remodeling backdrop. We’ll now examine how this earnings outperformance and sector strength could influence...
NasdaqGM:PSNY
NasdaqGM:PSNYAuto

Polestar (PSNY) Faces U.S. Sales Ban From 2027 As Europe Takes Center Stage

Polestar Automotive Holding UK (NasdaqGM:PSNY) has been denied authorization to sell new vehicles in the U.S. from 2027 under upcoming connected vehicle regulations. The U.S. Department of Commerce cited national security concerns tied to Chinese technology in its decision. Polestar plans to shift its future focus toward European markets as access to new U.S. vehicle sales is restricted. Polestar Automotive Holding UK, listed as NasdaqGM:PSNY, develops and sells premium electric vehicles, a...
NasdaqGS:MGNI
NasdaqGS:MGNIMedia

Is Magnite (MGNI) Undervalued Following Its Viasat Aviation Partnership?

Magnite’s Viasat partnership opens a new ad channel in the sky Magnite (MGNI) is back in focus after announcing a partnership with Viasat Aviation, bringing programmatic advertising to in-flight Wi-Fi and seat-back entertainment across thousands of aircraft worldwide. See our latest analysis for Magnite. The Viasat announcement comes after a strong rebound in Magnite’s share price, with a 30.32% 1 month share price return and 48.67% 3 month share price return, while the 1 year total...
NasdaqGS:MBLY
NasdaqGS:MBLYAuto Components

Mobileye Global (MBLY) Is Down 7.1% After Launching Fully Owned U.S. Robotaxi Business Plan

In June 2026, Mobileye Global announced plans to expand beyond supplying self-driving technology by launching a fully owned, vertically integrated autonomous ride-hailing business in a major U.S. city from 2027, starting with about 100 robotaxis and aiming to scale materially over the following five years. This move shifts Mobileye closer to an end‑to‑end mobility operator, combining its Mobileye Drive system with Moovit’s massive user base and global multimodal mobility platform into a...
NYSE:IBM
NYSE:IBMIT

IBM (IBM) Stock After Mixed Returns And AI Cloud Growth Narrative

Short-term traders and long-term holders alike may be asking the same question about International Business Machines right now: is the current share price giving you fair value for the risk you are taking? Over the past week the stock gained 3.7%, and it is up 3.0% over the last month, even though the year to date return is down 11.4% and the 1 year return is down 9.3%, compared to a much stronger 112.2% return over 3 years and 123.9% over 5 years. Recent headlines around International...
NYSE:BRO
NYSE:BROInsurance

Brown & Brown (BRO) Wins 2026 Workplace Honors For Mental Wellness Focus

Brown & Brown (NYSE:BRO) has been recognized in 2026 for its workplace culture and mental health programs. The company was named to the Best Workplaces in Financial Services & Insurance and Best Workplaces for Mental Wellness lists. It also received the Platinum Level Bell Seal for Workplace Mental Health for the fourth consecutive year. Brown & Brown, trading at $60.83, is drawing attention for company culture as much as for its role in the insurance sector. The stock has risen 2.9% over...
NasdaqGM:AUPH
NasdaqGM:AUPHBiotechs

Aurinia (AUPH) Expands Autoimmune Pipeline With Zetomipzomib – Is Its Dependence On Lupkynis Fading?

Aurinia Pharmaceuticals recently highlighted progress in broadening its autoimmune portfolio, advancing aritinercept in clinical development and integrating Kezar Life Sciences’ zetomipzomib program following its acquisition. This move shifts Aurinia’s story from dependence on Lupkynis alone toward a more diversified pipeline that could reshape its long-term autoimmune footprint. We’ll now consider how this broadened autoimmune pipeline, particularly the addition of zetomipzomib, may...
NYSE:UHS
NYSE:UHSHealthcare

Is Universal Health Services (UHS) Undervalued As Its Behavioral Health Story Faces Share Price Pressure?

Recent Share Performance and Business Profile Universal Health Services (UHS) has not been tied to a specific fresh headline event, but the stock’s recent performance and business mix across acute care and behavioral health services give investors several data points to assess. The company operates hospitals and behavioral health facilities across the United States, with revenue of about $17.76b and net income of roughly $1.52b, supported by both Acute Care Hospital Services and Behavioral...
NasdaqGM:SYM
NasdaqGM:SYMMachinery

Symbotic (SYM) Could Be 37% Below Fair Value Following Its Recent Slide

Symbotic (SYM) is back in focus after its stock declined more than the broader market, even as Wall Street braces for an earnings report that is expected to show very strong EPS and revenue growth. See our latest analysis for Symbotic. Over the past month, Symbotic’s share price return has fallen 22.89%, contributing to a 37.15% share price decline year to date. However, its 1 year total shareholder return of 9.71% and very large 5 year total shareholder return signal longer term momentum...
NYSE:MRK
NYSE:MRKPharmaceuticals

Merck (MRK) Stock After 64% One-Year Rally And Terns Deal Is It Priced Fairly?

If you are wondering whether Merck at US$125.45 still offers value after its strong run, this article explains what the current price may be implying about the stock. Merck's share price performance has been strong recently, with returns of 10.2% over the past 7 days, 4.8% over the past 30 days, 17.8% year to date, 64.5% over 1 year, 21.2% over 3 years and 88.0% over 5 years. Recent coverage of Merck has focused on its position in the pharmaceuticals space and how investors are reacting to...
NYSE:ENS
NYSE:ENSElectrical

EnerSys (ENS) After EZSelect Lite Launch Has Its Valuation Story Changed

EnerSys (ENS) has drawn investor attention after launching its EZSelect Lite battery room management system in Switzerland, aiming to automate battery selection and monitoring for industrial users and address inefficiencies in large fleet operations. See our latest analysis for EnerSys. The EZSelect Lite launch lands as EnerSys trades at US$226.34 per share, with a 1 day share price return of 3.38%, a 90 day share price return of 32.08% and a 1 year total shareholder return of 164.17%...
NYSE:SUNB
NYSE:SUNBTrade Distributors

Sunbelt Rentals Holdings (SUNB) Could Be 21% Overvalued As Record Results Lift Sentiment

Sunbelt Rentals Holdings (SUNB) just packed several signals into one update, combining record Q4 and full-year revenues with strong free cash flow, fresh 2027 guidance, a higher dividend, and ongoing share repurchases. See our latest analysis for Sunbelt Rentals Holdings. At a share price of $75.18, Sunbelt Rentals Holdings has seen a 15.18% 90 day share price return and a 23.21% 1 year total shareholder return. This suggests that longer term momentum remains intact despite a weaker 7 day...
NYSE:CCL
NYSE:CCLHospitality

Carnival (CCL) Earnings Beat Leaves Its Valuation Case Open To Debate

Carnival (CCL) is back in focus after reporting record quarterly revenue and earnings that topped analyst estimates, even though the stock fell as management paired the results with more cautious forward guidance. See our latest analysis for Carnival. The share price reaction around Carnival’s record quarter has been choppy, with the stock down 7.8% over the past week and 1.6% on the day, yet still showing a 17.6% 90 day share price return and a 67.6% three year total shareholder return that...
NasdaqGS:SNPS
NasdaqGS:SNPSSoftware

Synopsys (SNPS) Launches Multiphysics Fusion, Is The Stock Fully Priced?

Synopsys (SNPS) has just moved its AI driven Multiphysics Fusion platform into customer deployment, tying its electronic design automation tools directly to Ansys analysis at a moment of strong industry focus on advanced chip design. See our latest analysis for Synopsys. Despite the Multiphysics Fusion launch, Synopsys’ recent 1 month share price return is down 13.48%, though the 3 month share price return of 19.59% and 5 year total shareholder return of 63.00% point to stronger long term...
NYSE:STZ
NYSE:STZBeverage

Constellation Brands (STZ) Could Be 18% Undervalued Following Mixed Earnings Expectations

Mixed expectations ahead of Constellation Brands earnings Constellation Brands (STZ) is back in focus as investors look ahead to its upcoming first quarter fiscal 2027 earnings release, with forecasts pointing to modest profit growth but softer expectations after recent EPS estimate revisions. See our latest analysis for Constellation Brands. Constellation Brands shares recently moved up with a 1-day share price return of 1% and a 7-day share price return of 2.32%, although the 1-year total...
NasdaqGS:HLNE
NasdaqGS:HLNECapital Markets

Hamilton Lane (HLNE) After The Gridline Deal And The Case For A Discount

Hamilton Lane (HLNE) is in focus after Gridline said it will integrate the firm’s private markets data into AltComply, an AI-based diligence platform used by wealth managers, advisors and compliance teams. See our latest analysis for Hamilton Lane. Despite the Gridline partnership highlighting Hamilton Lane’s role in private markets data, recent momentum has been weak, with the share price down 44.23% year to date and the 1 year total shareholder return declining 46.07%. At the same time, the...
NYSE:IOT
NYSE:IOTSoftware

3 Software Stocks Retail Investors Are Watching for Growth as Inflation Cools

With inflation debates heating up again, Cathie Wood’s latest comments about cooler underlying price pressures and potential support from the Federal Reserve have put growth-oriented technology stocks back in focus. If inflation is closer to 2% than headline data suggests and policy eventually leans more toward supporting growth, companies with strong revenue expansion, solid balance sheets, and moderate volatility could stand out. This article looks at how that backdrop connects to our...
NYSE:LEG
NYSE:LEGConsumer Durables

Is Leggett & Platt (LEG) Undervalued After Its Mid Class Massage System Launch?

Leggett & Platt (LEG) is back on investors’ radar after its Leggett Dynamics subsidiary launched the Mid-Class Massage System, a non-electronic massage solution now in production with a global automaker and shortlisted for a 2026 industry award. See our latest analysis for Leggett & Platt. That launch comes as Leggett & Platt’s short term momentum has picked up, with a 30 day share price return of 12.62% and a 90 day share price return of 21.09%, while the 1 year total shareholder return of...
NasdaqGS:MYRG
NasdaqGS:MYRGConstruction

MYR Group (MYRG) Draws Fresh Analyst Support, Is The Upside Already Priced In?

Recent interest around MYR Group (MYRG) picked up after Oppenheimer initiated coverage with a Perform rating, highlighting growth opportunities in electrical transmission, data centers, and complex infrastructure, along with stronger free cash flow and insider selling concerns. See our latest analysis for MYR Group. At a share price of $487.33, MYR Group has seen momentum build, with a 3.67% 1 day share price return, 78.20% over 90 days and a 1 year total shareholder return of 170.44%. If you...
NYSE:ABBV
NYSE:ABBVBiotechs

AbbVie (ABBV) Wins EU Approval For Pediatric Skyrizi And Broader Maviret Use

AbbVie (NYSE:ABBV) received European Commission approval for Skyrizi to treat children and adolescents with moderate to severe plaque psoriasis. The company also secured approval for Maviret as the only therapy authorized in the EU for both acute and chronic hepatitis C in patients as young as three. These back to back decisions broaden AbbVie’s reach in immunology and virology, particularly in pediatric and earlier stage treatment settings. AbbVie is a large biopharmaceutical company with...